Barclays
KYMR icon

Barclays’s Kymera Therapeutics KYMR Stock Holding History

Barclays’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Sell
14,247
-126,260
-90% -$10M ﹤0.01% 2654
2025
Q4 		$10.9M Sell
140,507
-14,637
-9% -$988K ﹤0.01% 1624
2025
Q3 		$8.78M Buy
155,144
+11,963
+8% +$540K ﹤0.01% 1765
2025
Q2 		$6.25M Buy
143,181
+57,969
+68% +$2M ﹤0.01% 1930
2025
Q1 		$2.33M Sell
85,212
-15,793
-16% -$576K ﹤0.01% 2515
2024
Q4 		$4.06M Buy
101,005
+9,250
+10% +$418K ﹤0.01% 2346
2024
Q3 		$4.34M Buy
91,755
+42,662
+87% +$1.88M ﹤0.01% 2209
2024
Q2 		$1.47M Sell
49,093
-270,808
-85% -$9.38M ﹤0.01% 2356
2024
Q1 		$12.9M Sell
319,901
-61,880
-16% -$2.21M ﹤0.01% 1228
2023
Q4 		$9.72M Sell
381,781
-7,695
-2% -$138K ﹤0.01% 1540
2023
Q3 		$5.41M Buy
389,476
+4,493
+1% +$90.3K ﹤0.01% 1286
2023
Q2 		$8.85M Buy
384,983
+25,055
+7% +$718K 0.01% 1041
2023
Q1 		$10.7M Sell
359,928
-30,722
-8% -$991K ﹤0.01% 1129
2022
Q4 		$9.75M Buy
390,650
+37,656
+11% +$1M ﹤0.01% 1220
2022
Q3 		$7.68M Buy
352,994
+119,857
+51% +$3.16M 0.01% 959
2022
Q2 		$4.59M Buy
233,137
+226,360
+3,340% +$5.29M ﹤0.01% 1391
2022
Q1 		$287K Buy
+6,777
New +$286K ﹤0.01% 3229

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Barclays's KYMR Position: Q1 2026 in Review

Barclays reduced its Kymera Therapeutics (KYMR) stake by 90% in Q1 2026, selling an estimated $10M and leaving 14,247 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2654.

Barclays first reported a position in KYMR in Q1 2022 and has held it in 17 quarters since. The position peaked at $12.9M in Q1 2024. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Barclays held 14,247 shares of Kymera Therapeutics worth $1.19M as of Q1 2026.
  • Barclays sold 126,260 Kymera Therapeutics shares in Q1 2026, an estimated $10M.
  • Kymera Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2654 holding.
  • Barclays first reported a position in Kymera Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Kymera Therapeutics position peaked at $12.9M in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.